|
1
|
Neckers L: Hsp90 inhibitors as novel
cancer chemotherapeutic agents. Trends Mol Med. 8:S55–S61. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mitsiades CS, Mitsiades NS, McMullan CJ,
et al: Antimyeloma activity of heat shock protein-90 inhibition.
Blood. 107:1092–1100. 2006. View Article : Google Scholar
|
|
3
|
Chiosis G, Caldas Lopes E and Solit D:
Heat shock protein-90 inhibitors: a chronicle from geldanamycin to
today’s agents. Curr Opin Investig Drugs. 7:534–541.
2006.PubMed/NCBI
|
|
4
|
Teng SC, Chen YY, Su YN, et al: Direct
activation of HSP90A transcription by c-Myc contributes to
c-Myc-induced transformation. J Biol Chem. 279:14649–14655. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
McClellan AJ, Xia Y, Deutschbauer AM,
Davis RW, Gerstein M and Frydman J: Diverse cellular functions of
the Hsp90 molecular chaperone uncovered using systems approaches.
Cell. 131:121–135. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Okamoto J, Mikami I, Tominaga Y, et al:
Inhibition of Hsp90 leads to cell cycle arrest and apoptosis in
human malignant pleural mesothelioma. J Thorac Oncol. 3:1089–1095.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Trepel J, Mollapour M, Giaccone G and
Neckers L: Targeting the dynamic HSP90 complex in cancer. Nat Rev
Cancer. 10:537–549. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Banerji U: Heat shock protein 90 as a drug
target: some like it hot. Clin Cancer Res. 15:9–14. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Li Y, Zhang T, Schwartz SJ and Sun D: New
developments in Hsp90 inhibitors as anti-cancer therapeutics:
mechanisms, clinical perspective and more potential. Drug Resist
Updat. 12:17–27. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kamal A, Thao L, Sensintaffar J, et al: A
high-affinity conformation of Hsp90 confers tumour selectivity on
Hsp90 inhibitors. Nature. 425:407–410. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Isaacs JS, Xu W and Neckers L: Heat shock
protein 90 as a molecular target for cancer therapeutics. Cancer
Cell. 3:213–217. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Holzbeierlein JM, Windsperger A and
Vielhauer G: Hsp90: a drug target? Curr Oncol Rep. 12:95–101. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Amolins MW and Blagg BS: Natural product
inhibitors of Hsp90: potential leads for drug discovery. Mini Rev
Med Chem. 9:140–152. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Krishna P and Gloor G: The Hsp90 family of
proteins in Arabidopsis thaliana. Cell Stress Chaperones.
6:238–246. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Hainzl O, Lapina MC, Buchner J and Richter
K: The charged linker region is an important regulator of Hsp90
function. J Biol Chem. 284:22559–22567. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hawle P, Siepmann M, Harst A, Siderius M,
Reusch HP and Obermann WM: The middle domain of Hsp90 acts as a
discriminator between different types of client proteins. Mol Cell
Biol. 26:8385–8395. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lee CC, Lin TW, Ko TP and Wang AH: The
hexameric structures of human heat shock protein 90. PLoS One.
6:e199612011. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Prodromou C, Roe SM, O’Brien R, Ladbury
JE, Piper PW and Pearl LH: Identification and structural
characterization of the ATP/ADP-binding site in the Hsp90 molecular
chaperone. Cell. 90:65–75. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Whitesell L, Mimnaugh EG, De Costa B,
Myers CE and Neckers LM: Inhibition of heat shock protein
HSP90-pp60v-src heteroprotein complex formation by benzoquinone
ansamycins: essential role for stress proteins in oncogenic
transformation. Proc Natl Acad Sci USA. 91:8324–8328. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Karkoulis PK, Stravopodis DJ, Margaritis
LH and Voutsinas GE: 17-Allylamino-17-demethoxygeldanamycin induces
downregulation of critical Hsp90 protein clients and results in
cell cycle arrest and apoptosis of human urinary bladder cancer
cells. BMC Cancer. 10:4812010. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Babchia N, Calipel A, Mouriaux F, Faussat
AM and Mascarelli F: 17-AAG and 17-DMAG-induced inhibition of cell
proliferation through B-Raf downregulation in WT B-Raf-expressing
uveal melanoma cell lines. Invest Ophthalmol Vis Sci. 49:2348–2356.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Villa R, Folini M, Porta CD, et al:
Inhibition of telomerase activity by geldanamycin and
17-allylamino, 17-demethoxygeldanamycin in human melanoma cells.
Carcinogenesis. 24:851–859. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cervantes-Gomez F, Nimmanapalli R and
Gandhi V: Transcription inhibition of heat shock proteins: a
strategy for combination of 17-allylamino-17-demethoxygeldanamycin
and actinomycin D. Cancer Res. 69:3947–3954. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Messaoudi S, Peyrat JF, Brion JD and Alami
M: Heat-shock protein 90 inhibitors as antitumor agents: a survey
of the literature from 2005 to 2010. Expert Opin Ther Pat.
21:1501–1542. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Menzella HG, Tran TT, Carney JR, et al:
Potent non-benzoquinone ansamycin heat shock protein 90 inhibitors
from genetic engineering of Streptomyces hygroscopicus. J Med Chem.
52:1518–1521. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Turbyville TJ, Wijeratne EM, Liu MX, et
al: Search for Hsp90 inhibitors with potential anticancer activity:
isolation and SAR studies of radicicol and monocillin I from two
plant-associated fungi of the Sonoran desert. J Nat Prod.
69:178–184. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Pearl LH, Prodromou C and Workman P: The
Hsp90 molecular chaperone: an open and shut case for treatment.
Biochem J. 410:439–453. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Soga S, Shiotsu Y, Akinaga S and Sharma
SV: Development of radicicol analogues. Curr Cancer Drug Targets.
3:359–369. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chiosis G, Timaul MN, Lucas B, et al: A
small molecule designed to bind to the adenine nucleotide pocket of
Hsp90 causes Her2 degradation and the growth arrest and
differentiation of breast cancer cells. Chem Biol. 8:289–299. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kasibhatla SR, Hong K, Biamonte MA, et al:
Rationally designed high-affinity 2-amino-6-halopurine heat shock
protein 90 inhibitors that exhibit potent antitumor activity. J Med
Chem. 50:2767–2778. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Lundgren K, Zhang H, Brekken J, et al:
BIIB021, an orally available, fully synthetic small-molecule
inhibitor of the heat shock protein Hsp90. Mol Cancer Ther.
8:921–929. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Taldone T and Chiosis G: Purine-scaffold
Hsp90 inhibitors. Curr Top Med Chem. 9:1436–1446. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chandarlapaty S, Sawai A, Ye Q, et al:
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent
antitumor activity against HER kinase-dependent cancers. Clin
Cancer Res. 14:240–248. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jhaveri K, Taldone T, Modi S and Chiosis
G: Advances in the clinical development of heat shock protein 90
(Hsp90) inhibitors in cancers. Biochim Biophys Acta. 1823:742–755.
2012. View Article : Google Scholar :
|
|
35
|
Jhaveri K, Ochiana SO, Dunphy MP, et al:
Heat shock protein 90 inhibitors in the treatment of cancer:
current status and future directions. Expert Opin Investig Drugs.
23:611–628. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Raad II, Hachem RY, Abi-Said D, et al: A
prospective crossover randomized trial of novobiocin and rifampin
prophylaxis for the prevention of intravascular catheter infections
in cancer patients treated with interleukin-2. Cancer. 82:403–411.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Rappa G, Shyam K, Lorico A, Fodstad O and
Sartorelli AC: Structure-activity studies of novobiocin analogs as
modulators of the cytotoxicity of etoposide (VP-16). Oncol Res.
12:113–119. 2000. View Article : Google Scholar
|
|
38
|
Gormley NA, Orphanides G, Meyer A, Cullis
PM and Maxwell A: The interaction of coumarin antibiotics with
fragments of DNA gyrase B protein. Biochemistry. 35:5083–5092.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Marcu MG, Schulte TW and Neckers L:
Novobiocin and related coumarins and depletion of heat shock
protein 90-dependent signaling proteins. J Natl Cancer Inst.
92:242–248. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Peyrat JF, Messaoudi S, Brion JD and Alami
M: Inhibitors of the heat shock protein 90: from cancer clinical
trials to neurodegenerative diseases. Atlas Genet Cytogenet Oncol
Haematol. 15:89–105. 2011.
|
|
41
|
Le Bras G, Radanyi C, Peyrat JF, et al:
New novobiocin analogues as antiproliferative agents in breast
cancer cells and potential inhibitors of heat shock protein 90. J
Med Chem. 50:6189–6200. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Donnelly AC, Mays JR, Burlison JA, et al:
The design, synthesis, and evaluation of coumarin ring derivatives
of the novobiocin scaffold that exhibit antiproliferative activity.
J Org Chem. 73:8901–8920. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Radanyi C, Le Bras G, Marsaud V, et al:
Antiproliferative and apoptotic activities of tosylcyclonovobiocic
acids as potent heat shock protein 90 inhibitors in human cancer
cells. Cancer Lett. 274:88–94. 2009. View Article : Google Scholar
|
|
44
|
Burlison JA and Blagg BS: Synthesis and
evaluation of coumermycin A1 analogues that inhibit the Hsp90
protein folding machinery. Org Lett. 8:4855–4858. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Shelton SN, Shawgo ME, Matthews SB, et al:
KU135, a novel novobiocin-derived C-terminal inhibitor of the
90-kDa heat shock protein, exerts potent antiproliferative effects
in human leukemic cells. Mol Pharmacol. 76:1314–1322. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Samadi AK, Zhang X, Mukerji R, Donnelly
AC, Blagg BS and Cohen MS: A novel C-terminal HSP90 inhibitor KU135
induces apoptosis and cell cycle arrest in melanoma cells. Cancer
Lett. 312:158–167. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Eskew JD, Sadikot T, Morales P, et al:
Development and characterization of a novel C-terminal inhibitor of
Hsp90 in androgen dependent and independent prostate cancer cells.
BMC Cancer. 11:4682011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Matthews SB, Vielhauer GA, Manthe CA, et
al: Characterization of a novel novobiocin analogue as a putative
C-terminal inhibitor of heat shock protein 90 in prostate cancer
cells. Prostate. 70:27–36. 2010. View Article : Google Scholar
|
|
49
|
Zhao H, Moroni E, Colombo G and Blagg BS:
Identification of a new scaffold for hsp90 C-terminal inhibition.
ACS Med Chem Lett. 5:84–88. 2013. View Article : Google Scholar
|
|
50
|
Fujiki H, Suganuma M, Okabe S, et al:
Mechanistic findings of green tea as cancer preventive for humans.
Proc Soc Exp Biol Med. 220:225–228. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Palermo CM, Westlake CA and Gasiewicz TA:
Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene
transcription through an indirect mechanism involving binding to a
90 kDa heat shock protein. Biochemistry. 44:5041–5052. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Li Y, Zhang T, Jiang Y, Lee HF, Schwartz
SJ and Sun D: (−)-Epigallocatechin-3-gallate inhibits Hsp90
function by impairing Hsp90 association with cochaperones in
pancreatic cancer cell line Mia Paca-2. Mol Pharm. 6:1152–1159.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Yin Z, Henry EC and Gasiewicz TA:
(−)-Epigallocatechin-3-gallate is a novel Hsp90 inhibitor.
Biochemistry. 48:336–345. 2009. View Article : Google Scholar :
|
|
54
|
Tran PL, Kim SA, Choi HS, Yoon JH and Ahn
SG: Epigallocatechin-3-gallate suppresses the expression of HSP70
and HSP90 and exhibits anti-tumor activity in vitro and in vivo.
BMC Cancer. 10:2762010. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Jacquemont C, Simon JA, D’Andrea AD and
Taniguchi T: Non-specific chemical inhibition of the Fanconi anemia
pathway sensitizes cancer cells to cisplatin. Mol Cancer.
11:262012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Peron M, Bonvini P and Rosolen A: Effect
of inhibition of the ubiquitin-proteasome system and Hsp90 on
growth and survival of rhabdomyosarcoma cells in vitro. BMC Cancer.
12:2332012. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Kabakov AE, Kudryavtsev VA and Gabai VL:
Hsp90 inhibitors as promising agents for radiotherapy. J Mol Med
(Berl). 88:241–247. 2010. View Article : Google Scholar
|
|
58
|
Vaseva AV, Yallowitz AR, Marchenko ND, Xu
S and Moll UM: Blockade of Hsp90 by 17AAG antagonizes MDMX and
synergizes with Nutlin to induce p53-mediated apoptosis in solid
tumors. Cell Death Dis. 2:e1562011. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Shintani S, Zhang T, Aslam A, Sebastian K,
Yoshimura T and Hamakawa H: P53-dependent radiosensitizing effects
of Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin on human
oral squamous cell carcinoma cell lines. Int J Oncol. 29:1111–1117.
2006.PubMed/NCBI
|
|
60
|
To KK, Yu L, Liu S, Fu J and Cho CH:
Constitutive AhR activation leads to concomitant ABCG2-mediated
multidrug resistance in cisplatin-resistant esophageal carcinoma
cells. Mol Carcinog. 51:449–464. 2012. View Article : Google Scholar
|
|
61
|
Wu X, Wanders A, Wardega P, et al: Hsp90
is expressed and represents a therapeutic target in human
oesophageal cancer using the inhibitor
17-allylamino-17-demethoxygeldanamycin. Br J Cancer. 100:334–343.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Floris G, Debiec-Rychter M, Wozniak A, et
al: The heat shock protein 90 inhibitor IPI-504 induces KIT
degradation, tumor shrinkage, and cell proliferation arrest in
xenograft models of gastrointestinal stromal tumors. Mol Cancer
Ther. 10:1897–1908. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Floris G, Sciot R, Wozniak A, et al: The
novel HSP90 inhibitor, IPI-493, is highly effective in human
gastrostrointestinal stromal tumor xenografts carrying
heterogeneous KIT mutations. Clin Cancer Res. 17:5604–5614. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Smyth T, Van Looy T, Curry JE, et al: The
HSP90 inhibitor, AT13387, is effective against imatinib-sensitive
and -resistant gastrointestinal stromal tumor models. Mol Cancer
Ther. 11:1799–1808. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Lang SA, Moser C, Fichnter-Feigl S, et al:
Targeting heat-shock protein 90 improves efficacy of rapamycin in a
model of hepatocellular carcinoma in mice. Hepatology. 49:523–532.
2009. View Article : Google Scholar
|
|
66
|
Gloesenkamp C, Nitzsche B, Lim AR, et al:
Heat shock protein 90 is a promising target for effective growth
inhibition of gastrointestinal neuroendocrine tumors. Int J Oncol.
40:1659–1667. 2012.PubMed/NCBI
|
|
67
|
Oikonomou E, Koc M, Sourkova V, Andera L
and Pintzas A: Selective BRAFV600E inhibitor PLX4720, requires
TRAIL assistance to overcome oncogenic PIK3CA resistance. PLoS One.
6:e216322011. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Moser C, Lang SA, Kainz S, et al: Blocking
heat shock protein-90 inhibits the invasive properties and hepatic
growth of human colon cancer cells and improves the efficacy of
oxaliplatin in p53-deficient colon cancer tumors in vivo. Mol
Cancer Ther. 6:2868–2878. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Rakitina TV, Vasilevskaya IA and O’Dwyer
PJ: Inhibition of G1/S transition potentiates oxaliplatin-induced
cell death in colon cancer cell lines. Biochem Pharmacol.
73:1715–1726. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Vasilevskaya IA, Rakitina TV and O’Dwyer
PJ: Quantitative effects on c-Jun N-terminal protein kinase
signaling determine synergistic interaction of cisplatin and
17-allylamino-17-demethoxygeldanamycin in colon cancer cell lines.
Mol Pharmacol. 65:235–243. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
McNamara AV, Barclay M, Watson AJ and
Jenkins JR: Hsp90 inhibitors sensitise human colon cancer cells to
topoisomerase I poisons by depletion of key anti-apoptotic and cell
cycle checkpoint proteins. Biochem Pharmacol. 83:355–367. 2012.
View Article : Google Scholar
|
|
72
|
Tse AN, Sheikh TN, Alan H, Chou TC and
Schwartz GK: 90-kDa heat shock protein inhibition abrogates the
topoisomerase I poison-induced G2/M checkpoint in p53-null tumor
cells by depleting Chk1 and Wee1. Mol Pharmacol. 75:124–133. 2009.
View Article : Google Scholar :
|
|
73
|
Moran DM, Gawlak G, Jayaprakash MS, Mayar
S and Maki CG: Geldanamycin promotes premature mitotic entry and
micro-nucleation in irradiated p53/p21 deficient colon carcinoma
cells. Oncogene. 27:5567–5577. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Giessrigl B, Krieger S, Rosner M, et al:
Hsp90 stabilizes Cdc25A and counteracts heat shock-mediated Cdc25A
degradation and cell-cycle attenuation in pancreatic carcinoma
cells. Hum Mol Genet. 21:4615–4627. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Huston A, Leleu X, Jia X, et al: Targeting
Akt and heat shock protein 90 produces synergistic multiple myeloma
cell cytotoxicity in the bone marrow microenvironment. Clin Cancer
Res. 14:865–874. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Dote H, Cerna D, Burgan WE, Camphausen K
and Tofilon PJ: ErbB3 expression predicts tumor cell
radiosensitization induced by Hsp90 inhibition. Cancer Res.
65:6967–6975. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Li Y, Zhang T, Schwartz SJ and Sun D:
Sulforaphane potentiates the efficacy of 17-allylamino
17-demethoxygeldanamycin against pancreatic cancer through enhanced
abrogation of Hsp90 chaperone function. Nutr Cancer. 63:1151–1159.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
De Raedt T, Walton Z, Yecies JL, et al:
Exploiting cancer cell vulnerabilities to develop a combination
therapy for ras-driven tumors. Cancer Cell. 20:400–413. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Acquaviva J, Smith DL, Sang J, et al:
Targeting KRAS-mutant non-small cell lung cancer with the Hsp90
inhibitor ganetespib. Mol Cancer Ther. 11:2633–2643. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Proia DA, Sang J, He S, et al: Synergistic
activity of the Hsp90 inhibitor ganetespib with taxanes in
non-small cell lung cancer models. Invest New Drugs. 30:2201–2209.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Bao R, Lai CJ, Wang DG, et al: Targeting
heat shock protein 90 with CUDC-305 overcomes erlotinib resistance
in non-small cell lung cancer. Mol Cancer Ther. 8:3296–3306. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Bao R, Lai CJ, Qu H, et al: CUDC-305, a
novel synthetic HSP90 inhibitor with unique pharmacologic
properties for cancer therapy. Clin Cancer Res. 15:4046–4057. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Koizumi H, Yamada T, Takeuchi S, et al:
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs
in EGFR-mutant lung cancer by decreasing client protein expression
and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Xu L, Kikuchi E, Xu C, et al: Combined
EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of
lung cancers codriven by mutant EGFR containing T790M and MET.
Cancer Res. 72:3302–3311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Rice JW, Veal JM, Barabasz A, et al:
Targeting of multiple signaling pathways by the Hsp90 inhibitor
SNX-2112 in EGFR resistance models as a single agent or in
combination with erlotinib. Oncol Res. 18:229–242. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Tsai MS, Weng SH, Chen HJ, et al:
Inhibition of p38 MAPK-dependent excision repair
cross-complementing 1 expression decreases the DNA repair capacity
to sensitize lung cancer cells to etoposide. Mol Cancer Ther.
11:561–571. 2012. View Article : Google Scholar
|
|
87
|
Weng SH, Tseng SC, Huang YC, Chen HJ and
Lin YW: Inhibition of thymidine phosphorylase expression by using
an HSP90 inhibitor potentiates the cytotoxic effect of cisplatin in
non-small-cell lung cancer cells. Biochem Pharmacol. 84:126–136.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Katayama R, Khan TM, Benes C, et al:
Therapeutic strategies to overcome crizotinib resistance in
non-small cell lung cancers harboring the fusion oncogene EML4-ALK.
Proc Natl Acad Sci USA. 108:7535–7540. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Normant E, Paez G, West KA, et al: The
Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces
tumor regression in ALK-driven NSCLC models. Oncogene.
30:2581–2586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Solit DB, Osman I, Polsky D, et al: Phase
II trial of 17-allylamino-17-demethoxygeldanamycin in patients with
metastatic melanoma. Clin Cancer Res. 14:8302–8307. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Heuckmann JM, Balke-Want H, Malchers F, et
al: Differential protein stability and ALK inhibitor sensitivity of
EML4-ALK fusion variants. Clin Cancer Res. 18:4682–4690. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Sang J, Acquaviva J, Friedland JC, et al:
Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK
inhibitor resistance in non-small cell lung cancer. Cancer Discov.
3:430–443. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Koll TT, Feis SS, Wright MH, et al: HSP90
inhibitor, DMAG, synergizes with radiation of lung cancer cells by
interfering with base excision and ATM-mediated DNA repair. Mol
Cancer Ther. 7:1985–1992. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Segawa T, Fujii Y, Tanaka A, et al:
Radiosensitization of human lung cancer cells by the novel
purine-scaffold Hsp90 inhibitor, PU-H71. Int J Mol Med. 33:559–564.
2014.
|
|
95
|
Kim YM and Pyo H: Cooperative enhancement
of radiosensitivity after combined treatment of
17-(allylamino)-17-demethoxygeldanamycin and celecoxib in human
lung and colon cancer cell lines. DNA Cell Biol. 31:15–29. 2012.
View Article : Google Scholar :
|
|
96
|
Sudo M, Chin TM, Mori S, et al: Inhibiting
proliferation of gefitinib-resistant, non-small cell lung cancer.
Cancer Chemother Pharmacol. 71:1325–1334. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Wainberg ZA, Anghel A, Rogers AM, et al:
Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified
trastuzumab-resistant breast and gastric cancer. Mol Cancer Ther.
12:509–519. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Ono N, Yamazaki T, Nakanishi Y, et al:
Preclinical antitumor activity of the novel heat shock protein 90
inhibitor CH5164840 against human epidermal growth factor receptor
2 (HER2)-overexpressing cancers. Cancer Sci. 103:342–349. 2012.
View Article : Google Scholar
|
|
99
|
Scaltriti M, Serra V, Normant E, et al:
Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive
trastuzumab-resistant breast cancer. Mol Cancer Ther. 10:817–824.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Chandarlapaty S, Scaltriti M, Angelini P,
et al: Inhibitors of HSP90 block p95-HER2 signaling in
Trastuzumab-resistant tumors and suppress their growth. Oncogene.
29:325–334. 2010. View Article : Google Scholar
|
|
101
|
Meng Q, Chen X, Sun L, Zhao C, Sui G and
Cai L: Carbamazepine promotes Her-2 protein degradation in breast
cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
Mol Cell Biochem. 348:165–171. 2011. View Article : Google Scholar
|
|
102
|
Solit DB, Basso AD, Olshen AB, Scher HI
and Rosen N: Inhibition of heat shock protein 90 function
down-regulates Akt kinase and sensitizes tumors to Taxol. Cancer
Res. 63:2139–2144. 2003.PubMed/NCBI
|
|
103
|
Wong C and Chen S: Heat shock protein 90
inhibitors: new mode of therapy to overcome endocrine resistance.
Cancer Res. 69:8670–8677. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Wong C, Wang X, Smith D, Reddy K and Chen
S: AKT-aro and HER2-aro, models for de novo resistance to aromatase
inhibitors; molecular characterization and inhibitor response
studies. Breast Cancer Res Treat. 134:671–681. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Pashtan I, Tsutsumi S, Wang S, Xu W and
Neckers L: Targeting Hsp90 prevents escape of breast cancer cells
from tyrosine kinase inhibition. Cell Cycle. 7:2936–2941. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
106
|
Palacios C, Lopez-Perez AI and Lopez-Rivas
A: Down-regulation of RIP expression by
17-dimethylaminoethylamino-17-demethoxygeldanamycin promotes
TRAIL-induced apoptosis in breast tumor cells. Cancer Lett.
287:207–215. 2010. View Article : Google Scholar
|
|
107
|
Stecklein SR, Kumaraswamy E, Behbod F, et
al: BRCA1 and HSP90 cooperate in homologous and non-homologous DNA
double-strand-break repair and G2/M checkpoint activation. Proc
Natl Acad Sci USA. 109:13650–13655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Benezra R, Henke E, Ciarrocchi A, et al:
Induction of complete regressions of oncogene-induced breast tumors
in mice. Cold Spring Harb Symp Quant Biol. 70:375–381. 2005.
View Article : Google Scholar
|
|
109
|
Smith V, Hobbs S, Court W, Eccles S,
Workman P and Kelland LR: ErbB2 overexpression in an ovarian cancer
cell line confers sensitivity to the HSP90 inhibitor geldanamycin.
Anticancer Res. 22:1993–1999. 2002.PubMed/NCBI
|
|
110
|
Solar P, Horvath V, Kleban J, et al: Hsp90
inhibitor geldanamycin increases the sensitivity of resistant
ovarian adenocarcinoma cell line A2780cis to cisplatin. Neoplasma.
54:127–130. 2007.PubMed/NCBI
|
|
111
|
Sain N, Krishnan B, Ormerod MG, et al:
Potentiation of paclitaxel activity by the HSP90 inhibitor
17-allylamino-17-demethoxygeldanamycin in human ovarian carcinoma
cell lines with high levels of activated AKT. Mol Cancer Ther.
5:1197–1208. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
Mollapour M, Tsutsumi S, Donnelly AC, et
al: Swe1 Wee1-dependent tyrosine phosphorylation of Hsp90 regulates
distinct facets of chaperone function. Mol Cell. 37:333–343. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
113
|
Iwai A, Bourboulia D, Mollapour M, et al:
Combined inhibition of Wee1 and Hsp90 activates intrinsic apoptosis
in cancer cells. Cell Cycle. 11:3649–3655. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Lamoureux F, Thomas C, Yin MJ, et al:
Clusterin inhibition using OGX-011 synergistically enhances Hsp90
inhibitor activity by suppressing the heat shock response in
castrate-resistant prostate cancer. Cancer Res. 71:5838–5849. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
115
|
O’Malley KJ, Langmann G, Ai J,
Ramos-Garcia R, Vessella RL and Wang Z: Hsp90 inhibitor 17-AAG
inhibits progression of LuCaP35 xenograft prostate tumors to
castration resistance. Prostate. 72:1117–1123. 2012. View Article : Google Scholar
|
|
116
|
Huang HC, Yang Y, Nanda A, Koria P and
Rege K: Synergistic administration of photothermal therapy and
chemotherapy to cancer cells using polypeptide-based degradable
plasmonic matrices. Nanomedicine (Lond). 6:459–473. 2011.
View Article : Google Scholar
|
|
117
|
Lamottke B, Kaiser M, Mieth M, et al: The
novel, orally bioavailable HSP90 inhibitor NVP-HSP990 induces cell
cycle arrest and apoptosis in multiple myeloma cells and acts
synergistically with melphalan by increased cleavage of caspases.
Eur J Haematol. 88:406–415. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
118
|
Stuhmer T, Iskandarov K, Gao Z, et al:
Preclinical activity of the novel orally bioavailable HSP90
inhibitor NVP-HSP990 against multiple myeloma cells. Anticancer
Res. 32:453–462. 2012.PubMed/NCBI
|
|
119
|
Chatterjee M, Andrulis M, Stuhmer T, et
al: The PI3K/Akt signaling pathway regulates the expression of
Hsp70, which critically contributes to Hsp90-chaperone function and
tumor cell survival in multiple myeloma. Haematologica.
98:1132–1141. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Kaiser M, Lamottke B, Mieth M, et al:
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with
histone deacetylase inhibitors, melphalan, or doxorubicin in
multiple myeloma. Eur J Haematol. 84:337–344. 2010. View Article : Google Scholar
|
|
121
|
Yasui H, Hideshima T, Ikeda H, et al: BIRB
796 enhances cytotoxicity triggered by bortezomib, heat shock
protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38
mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma
cell lines and inhibits paracrine tumour growth. Br J Haematol.
136:414–423. 2007. View Article : Google Scholar
|
|
122
|
Weigert O, Lane AA, Bird L, et al: Genetic
resistance to JAK2 enzymatic inhibitors is overcome by HSP90
inhibition. J Exp Med. 209:259–273. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Fiskus W, Verstovsek S, Manshouri T, et
al: Heat shock protein 90 inhibitor is synergistic with JAK2
inhibitor and overcomes resistance to JAK2-TKI in human
myeloproliferative neoplasm cells. Clin Cancer Res. 17:7347–7358.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Fiskus W, Rao R, Fernandez P, et al:
Molecular and biologic characterization and drug sensitivity of
pan-histone deacetylase inhibitor-resistant acute myeloid leukemia
cells. Blood. 112:2896–2905. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kaufmann SH, Karp JE, Litzow MR, et al:
Phase I and pharmacological study of cytarabine and tanespimycin in
relapsed and refractory acute leukemia. Haematologica.
96:1619–1626. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Best OG, Che Y, Singh N, Forsyth C,
Christopherson RI and Mulligan SP: The Hsp90 inhibitor SNX-7081
synergizes with and restores sensitivity to fludarabine in chronic
lymphocytic leukemia cells with lesions in the TP53 pathway: a
potential treatment strategy for fludarabine refractory disease.
Leuk Lymphoma. 53:1367–1375. 2012. View Article : Google Scholar
|
|
127
|
Jones DT, Addison E, North JM, et al:
Geldanamycin and herbimycin A induce apoptotic killing of B chronic
lymphocytic leukemia cells and augment the cells’ sensitivity to
cytotoxic drugs. Blood. 103:1855–1861. 2004. View Article : Google Scholar
|
|
128
|
Walsby E, Pearce L, Burnett AK, Fegan C
and Pepper C: The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-kappaB
signaling, overcomes microenvironmental cytoprotection and is
highly synergistic with fludarabine in primary CLL cells.
Oncotarget. 3:525–534. 2012.PubMed/NCBI
|
|
129
|
Johnson AJ, Wagner AJ, Cheney CM, et al:
Rituximab and 17-allylamino-17-demethoxygeldanamycin induce
synergistic apoptosis in B-cell chronic lymphocytic leukaemia. Br J
Haematol. 139:837–844. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Blagosklonny MV, Fojo T, Bhalla KN, et al:
The Hsp90 inhibitor geldanamycin selectively sensitizes
Bcr-Abl-expressing leukemia cells to cytotoxic chemotherapy.
Leukemia. 15:1537–1543. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
131
|
Peng C, Brain J, Hu Y, et al: Inhibition
of heat shock protein 90 prolongs survival of mice with
BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells.
Blood. 110:678–685. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
132
|
Tauchi T, Okabe S, Ashihara E, Kimura S,
Maekawa T and Ohyashiki K: Combined effects of novel heat shock
protein 90 inhibitor NVP-AUY922 and nilotinib in a random
mutagenesis screen. Oncogene. 30:2789–2797. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Demidenko ZN, An WG, Lee JT, Romanova LY,
McCubrey JA and Blagosklonny MV: Kinase-addiction and bi-phasic
sensitivity-resistance of Bcr-Abl- and Raf-1-expressing cells to
imatinib and geldanamycin. Cancer Biol Ther. 4:484–490. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Roue G, Perez-Galan P, Mozos A, et al: The
Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle
cell lymphoma in vitro and in vivo by down-regulation of the
prosur-vival ER chaperone BiP/Grp78. Blood. 117:1270–1279. 2011.
View Article : Google Scholar
|
|
135
|
Dungey FA, Caldecott KW and Chalmers AJ:
Enhanced radiosensitization of human glioma cells by combining
inhibition of poly(ADP-ribose) polymerase with inhibition of heat
shock protein 90. Mol Cancer Ther. 8:2243–2254. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Ohba S, Hirose Y, Yoshida K, Yazaki T and
Kawase T: Inhibition of 90-kD heat shock protein potentiates the
cytotoxicity of chemotherapeutic agents in human glioma cells. J
Neurosurg. 112:33–42. 2010. View Article : Google Scholar
|
|
137
|
Siegelin MD, Habel A and Gaiser T: 17-AAG
sensitized malignant glioma cells to death-receptor mediated
apoptosis. Neurobiol Dis. 33:243–249. 2009. View Article : Google Scholar
|
|
138
|
Sauvageot CM, Weatherbee JL, Kesari S, et
al: Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell
lines and tumorigenic glioma stem cells. Neuro Oncol. 11:109–121.
2009. View Article : Google Scholar :
|
|
139
|
Paraiso KH, Haarberg HE, Wood E, et al:
The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance
mediated through diverse mechanisms. Clin Cancer Res. 18:2502–2514.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Ito A, Saito H, Mitobe K, et al:
Inhibition of heat shock protein 90 sensitizes melanoma cells to
thermosensitive ferromagnetic particle-mediated hyperthermia with
low Curie temperature. Cancer Sci. 100:558–564. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Acquaviva J, Smith DL, Jimenez JP, et al:
Overcoming acquired BRAF inhibitor resistance in melanoma via
targeted inhibition of Hsp90 with ganetespib. Mol Cancer Ther.
13:353–363. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Tatokoro M, Koga F, Yoshida S, et al:
Potential role of Hsp90 inhibitors in overcoming cisplatin
resistance of bladder cancer-initiating cells. Int J Cancer.
131:987–996. 2012. View Article : Google Scholar
|
|
143
|
Yoshida S, Koga F, Tatokoro M, et al:
Low-dose Hsp90 inhibitors tumor-selectively sensitize bladder
cancer cells to chemoradiotherapy. Cell Cycle. 10:4291–4299. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Sato A and Asano T, Ito K and Asano T:
17-Allylamino-17-demethoxygeldanamycin and ritonavir inhibit renal
cancer growth by inhibiting the expression of heat shock factor-1.
Int J Oncol. 41:46–52. 2012.PubMed/NCBI
|
|
145
|
Ma L, Sato F, Sato R, et al: Dual
targeting of heat shock proteins 90 and 70 promotes cell death and
enhances the anticancer effect of chemotherapeutic agents in
bladder cancer. Oncol Rep. 31:2482–2492. 2014.PubMed/NCBI
|
|
146
|
Yin X, Zhang H, Lundgren K, Wilson L,
Burrows F and Shores CG: BIIB021, a novel Hsp90 inhibitor,
sensitizes head and neck squamous cell carcinoma to radiotherapy.
Int J Cancer. 126:1216–1225. 2010.
|
|
147
|
Misso G, Giuberti G, Lombardi A, et al:
Pharmacological inhibition of HSP90 and ras activity as a new
strategy in the treatment of HNSCC. J Cell Physiol. 228:130–141.
2013. View Article : Google Scholar
|
|
148
|
Lee CH, Hong HM, Chang YY and Chang WW:
Inhibition of heat shock protein (Hsp) 27 potentiates the
suppressive effect of Hsp90 inhibitors in targeting breast cancer
stem-like cells. Biochimie. 94:1382–1389. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Newman B, Liu Y, Lee HF, Sun D and Wang Y:
HSP90 inhibitor 17-AAG selectively eradicates lymphoma stem cells.
Cancer Res. 72:4551–4561. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Kelland LR, Sharp SY, Rogers PM, Myers TG
and Workman P: DT-Diaphorase expression and tumor cell sensitivity
to 17-allylamino, 17-demethoxygeldanamycin, an inhibitor of heat
shock protein 90. J Natl Cancer Inst. 91:1940–1949. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Gaspar N, Sharp SY, Pacey S, et al:
Acquired resistance to 17-allylamino-17-demethoxygeldanamycin
(17-AAG, tanespimycin) in glioblastoma cells. Cancer Res.
69:1966–1975. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Zhang H, Neely L, Lundgren K, et al:
BIIB021, a synthetic Hsp90 inhibitor, has broad application against
tumors with acquired multidrug resistance. Int J Cancer.
126:1226–1234. 2010.
|
|
153
|
Sharp SY, Boxall K, Rowlands M, et al: In
vitro biological characterization of a novel, synthetic diaryl
pyrazole resorcinol class of heat shock protein 90 inhibitors.
Cancer Res. 67:2206–2216. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Sharp SY, Prodromou C, Boxall K, et al:
Inhibition of the heat shock protein 90 molecular chaperone in
vitro and in vivo by novel, synthetic, potent resorcinylic
pyrazole/isoxazole amide analogues. Mol Cancer Ther. 6:1198–1211.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Gaspar N, Sharp SY, Eccles SA, et al:
Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in
adult and pediatric glioblastoma. Mol Cancer Ther. 9:1219–1233.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
McCollum AK, Teneyck CJ, Sauer BM, Toft DO
and Erlichman C: Up-regulation of heat shock protein 27 induces
resistance to 17-allylamino-demethoxygeldanamycin through a
glutathione-mediated mechanism. Cancer Res. 66:10967–10975. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Sharp SY, Roe SM, Kazlauskas E, et al:
Co-crystalization and in vitro biological characterization of
5-aryl-4-(5-substituted-2-4-dihydroxyphenyl)-1,2,3-thiadiazole
Hsp90 inhibitors. PLoS One. 7:e446422012. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
McConnell JR and McAlpine SR: Heat shock
proteins 27, 40, and 70 as combinational and dual therapeutic
cancer targets. Bioorg Med Chem Lett. 23:1923–1928. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Lamoureux F, Thomas C, Yin MJ, Fazli L,
Zoubeidi A and Gleave ME: Suppression of heat shock protein 27
using OGX-427 induces endoplasmic reticulum stress and potentiates
heat shock protein 90 inhibitors to delay castrate-resistant
prostate cancer. Eur Urol. 66:145–155. 2013. View Article : Google Scholar
|
|
160
|
Guo F, Rocha K, Bali P, et al: Abrogation
of heat shock protein 70 induction as a strategy to increase
antileukemia activity of heat shock protein 90 inhibitor
17-allylamino-demethoxy geldanamycin. Cancer Res. 65:10536–10544.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Pimienta G, Herbert KM and Regan L: A
compound that inhibits the HOP-Hsp90 complex formation and has
unique killing effects in breast cancer cell lines. Mol Pharm.
8:2252–2261. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Miyagawa T, Saito H, Minamiya Y, et al:
Inhibition of Hsp90 and 70 sensitizes melanoma cells to
hyperthermia using ferromagnetic particles with a low Curie
temperature. Int J Clin Oncol. 19:722–730. 2014. View Article : Google Scholar
|
|
163
|
Ronnen EA, Kondagunta GV, Ishill N, et al:
A phase II trial of 17-(Allylamino)-17-demethoxygeldanamycin in
patients with papillary and clear cell renal cell carcinoma. Invest
New Drugs. 24:543–546. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Heath EI, Hillman DW, Vaishampayan U, et
al: A phase II trial of 17-allylamino-17-demethoxygeldanamycin in
patients with hormone-refractory metastatic prostate cancer. Clin
Cancer Res. 14:7940–7946. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Sequist LV, Gettinger S, Senzer NN, et al:
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in
patients with molecularly defined non-small-cell lung cancer. J
Clin Oncol. 28:4953–4960. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Oh WK, Galsky MD, Stadler WM, et al:
Multicenter phase II trial of the heat shock protein 90 inhibitor,
retaspimycin hydrochloride (IPI-504), in patients with
castration-resistant prostate cancer. Urology. 78:626–630. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Richardson PG, Chanan-Khan AA, Lonial S,
et al: Tanespimycin and bortezomib combination treatment in
patients with relapsed or relapsed and refractory multiple myeloma:
results of a phase 1/2 study. Br J Haematol. 153:729–740. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Modi S, Stopeck A, Linden H, et al: HSP90
inhibition is effective in breast cancer: a phase II trial of
tanespimycin (17-AAG) plus trastuzumab in patients with
HER2-positive metastatic breast cancer progressing on trastuzumab.
Clin Cancer Res. 17:5132–5139. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Gartner EM, Silverman P, Simon M, et al: A
phase II study of 17-allylamino-17-demethoxygeldanamycin in
metastatic or locally advanced, unresectable breast cancer. Breast
Cancer Res Treat. 131:933–937. 2012. View Article : Google Scholar
|
|
170
|
Pacey S, Gore M, Chao D, et al: A phase II
trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG,
tanespimycin) in patients with metastatic melanoma. Invest New
Drugs. 30:341–349. 2012. View Article : Google Scholar
|
|
171
|
Socinski MA, Goldman J, El-Hariry I, et
al: A multicenter phase II study of ganetespib monotherapy in
patients with genotypically defined advanced non-small cell lung
cancer. Clin Cancer Res. 19:3068–3077. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Modi S, Saura C, Henderson C, et al: A
multicenter trial evaluating retaspimycin HCL (IPI-504) plus
trastuzumab in patients with advanced or metastatic HER2-positive
breast cancer. Breast Cancer Res Treat. 139:107–113. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Jhaveri K, Chandarlapaty S, Lake D, et al:
A phase II open-label study of ganetespib, a novel heat shock
protein 90 inhibitor for patients with metastatic breast cancer.
Clin Breast Cancer. 14:154–160. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Ui T, Morishima K, Saito S, et al: The
HSP90 inhibitor 17-N-allylamino-17-demethoxy geldanamycin (17-AAG)
synergizes with cisplatin and induces apoptosis in
cisplatin-resistant esophageal squamous cell carcinoma cell lines
via the Akt/XIAP pathway. Oncol Rep. 31:619–624. 2014.
|
|
175
|
Akimoto T, Nonaka T, Harashima K, Sakurai
H, Ishikawa H and Mitsuhashi N: Radicicol potentiates heat-induced
cell killing in a human oesophageal cancer cell line: the Hsp90
chaperone complex as a new molecular target for enhancement of
thermosensitivity. Int J Radiat Biol. 80:483–492. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Burkitt M, Magee C, O’Connor D, Campbell
F, Cornford P and Greenhalf W: Potentiation of chemotherapeutics by
the Hsp90 antagonist geldanamycin requires a steady serum
condition. Mol Carcinog. 46:466–475. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Cao X, Bloomston M, Zhang T, et al:
Synergistic antipancreatic tumor effect by simultaneously targeting
hypoxic cancer cells with HSP90 inhibitor and glycolysis inhibitor.
Clin Cancer Res. 14:1831–1839. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Cao X, Jia G, Zhang T, et al: Non-invasive
MRI tumor imaging and synergistic anticancer effect of HSP90
inhibitor and glycolysis inhibitor in RIP1-Tag2 transgenic
pancreatic tumor model. Cancer Chemother Pharmacol. 62:985–994.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Zhang T, Li Y, Zhu Z, Gu M, Newman B and
Sun D: MEK inhibition potentiates the activity of Hsp90 inhibitor
17-AAG against pancreatic cancer cells. Mol Pharm. 7:1576–1584.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Milanovic D, Firat E, Grosu AL and
Niedermann G: Increased radiosensitivity and radiothermosensitivity
of human pancreatic MIA PaCa-2 and U251 glioblastoma cell lines
treated with the novel Hsp90 inhibitor NVP-HSP990. Radiat Oncol.
8:422013. View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Machida H, Matsumoto Y, Shirai M and
Kubota N: Geldanamycin, an inhibitor of Hsp90, sensitizes human
tumour cells to radiation. Int J Radiat Biol. 79:973–980. 2003.
View Article : Google Scholar
|
|
182
|
Vasilevskaya IA and O’Dwyer PJ:
17-Allylamino-17-demethoxygeldanamycin overcomes TRAIL resistance
in colon cancer cell lines. Biochem Pharmacol. 70:580–589. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Holmes JL, Sharp SY, Hobbs S and Workman
P: Silencing of HSP90 cochaperone AHA1 expression decreases client
protein activation and increases cellular sensitivity to the HSP90
inhibitor 17-allylamino-17-demethoxygeldanamycin. Cancer Res.
68:1188–1197. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Saturno G, Valenti M, De Haven Brandon A,
et al: Combining trail with PI3 kinase or HSP90 inhibitors enhances
apoptosis in colorectal cancer cells via suppression of survival
signaling. Oncotarget. 4:1185–1198. 2013.PubMed/NCBI
|
|
185
|
He S, Smith DL, Sequeira M, Sang J, Bates
RC and Proia DA: The HSP90 inhibitor ganetespib has chemosensitizer
and radiosensitizer activity in colorectal cancer. Invest New
Drugs. 32:577–586. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Nguyen DM, Chen A, Mixon A and Schrump DS:
Sequence-dependent enhancement of paclitaxel toxicity in non-small
cell lung cancer by 17-allylamino 17-demethoxygeldanamycin. J
Thorac Cardiovasc Surg. 118:908–915. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Wen W, Liu W, Shao Y and Chen L:
VER-155008, a small molecule inhibitor of HSP70 with potent
anti-cancer activity on lung cancer cell lines. Exp Biol Med
(Maywood). 239:638–645. 2014. View Article : Google Scholar
|
|
188
|
Zismanov V, Drucker L and Gottfried M: ER
homeostasis and motility of NSCLC cell lines can be therapeutically
targeted with combined Hsp90 and HDAC inhibitors. Pulm Pharmacol
Ther. 26:388–394. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Zismanov V, Drucker L and Gottfried M:
Combined inhibition of Hsp90 and the proteasome affects NSCLC
proteostasis and attenuates cell migration. Anticancer Drugs.
25:998–1006. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Chen Z, Akbay E, Mikse O, et al:
Co-clinical trials demonstrate superiority of crizotinib to
chemotherapy in ALK-rearranged non-small cell lung cancer and
predict strategies to overcome resistance. Clin Cancer Res.
20:1204–1211. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Miyajima N, Tsutsumi S, Sourbier C, et al:
The HSP90 inhibitor ganetespib synergizes with the MET kinase
inhibitor crizotinib in both crizotinib-sensitive and -resistant
MET-driven tumor models. Cancer Res. 73:7022–7033. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
192
|
Smith DL, Acquaviva J, Sequeira M, et al:
The HSP90 inhibitor ganetespib potentiates the antitumor activity
of EGFR tyrosine kinase inhibition in mutant and wild-type
non-small cell lung cancer. Target Oncol. Aug 1–2014.(Epub ahead of
print). View Article : Google Scholar : PubMed/NCBI
|
|
193
|
Ono N, Yamazaki T, Tsukaguchi T, et al:
Enhanced antitumor activity of erlotinib in combination with the
Hsp90 inhibitor CH5164840 against non-small-cell lung cancer.
Cancer Sci. 104:1346–1352. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
194
|
Jang WJ, Jung SK, Kang JS, et al:
Anti-tumor activity of WK88-1, a novel geldanamycin derivative, in
gefitinib-resistant NSCLCs with Met amplification. Cancer Sci. Aug
13–2014.(Epub ahead of print). View Article : Google Scholar
|
|
195
|
Ma Y, Lakshmikanthan V, Lewis RW and Kumar
MV: Sensitization of TRAIL-resistant cells by inhibition of heat
shock protein 90 with low-dose geldanamycin. Mol Cancer Ther.
5:170–178. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
196
|
Senju M, Sueoka N, Sato A, et al: Hsp90
inhibitors cause G2/M arrest associated with the reduction of
Cdc25C and Cdc2 in lung cancer cell lines. J Cancer Res Clin Oncol.
132:150–158. 2006. View Article : Google Scholar
|
|
197
|
Russell JS, Burgan W, Oswald KA,
Camphausen K and Tofilon PJ: Enhanced cell killing induced by the
combination of radiation and the heat shock protein 90 inhibitor
17-allylamino-17-demethoxygeldanamycin: a multitarget approach to
radiosensitization. Clin Cancer Res. 9:3749–3755. 2003.PubMed/NCBI
|
|
198
|
Bisht KS, Bradbury CM, Mattson D, et al:
Geldanamycin and 17-allylamino-17-demethoxygeldanamycin potentiate
the in vitro and in vivo radiation response of cervical tumor cells
via the heat shock protein 90-mediated intracellular signaling and
cytotoxicity. Cancer Res. 63:8984–8995. 2003.PubMed/NCBI
|
|
199
|
Sawai A, Chandarlapaty S, Greulich H, et
al: Inhibition of Hsp90 down-regulates mutant epidermal growth
factor receptor (EGFR) expression and sensitizes EGFR mutant tumors
to paclitaxel. Cancer Res. 68:589–596. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
200
|
Bai L, Xu S, Chen W, et al: Blocking
NF-kappaB and Akt by Hsp90 inhibition sensitizes Smac mimetic
compound 3-induced extrinsic apoptosis pathway and results in
synergistic cancer cell death. Apoptosis. 16:45–54. 2011.
View Article : Google Scholar :
|
|
201
|
Mimnaugh EG, Xu W, Vos M, et al:
Simultaneous inhibition of hsp 90 and the proteasome promotes
protein ubiquitination, causes endoplasmic reticulum-derived
cytosolic vacuolization, and enhances antitumor activity. Mol
Cancer Ther. 3:551–566. 2004.PubMed/NCBI
|
|
202
|
Raja SM, Clubb RJ, Bhattacharyya M, et al:
A combination of Trastuzumab and 17-AAG induces enhanced
ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation
and cytotoxicity in ErbB2-overexpressing breast cancer cells.
Cancer Biol Ther. 7:1630–1640. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
203
|
Zsebik B, Citri A, Isola J, Yarden Y,
Szollosi J and Vereb G: Hsp90 inhibitor 17-AAG reduces ErbB2 levels
and inhibits proliferation of the trastuzumab resistant breast
tumor cell line JIMT-1. Immunol Lett. 104:146–155. 2006. View Article : Google Scholar
|
|
204
|
Roforth MM and Tan C: Combination of
rapamycin and 17-allylamino-17-demethoxygeldanamycin abrogates Akt
activation and potentiates mTOR blockade in breast cancer cells.
Anticancer Drugs. 19:681–688. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
205
|
Munster PN, Basso A, Solit D, Norton L and
Rosen N: Modulation of Hsp90 function by ansamycins sensitizes
breast cancer cells to chemotherapy-induced apoptosis in an RB- and
schedule-dependent manner. See: E A Sausville, Combining cytotoxics
and 17-allylamino, 17-demethoxygeldanamycin: sequence and tumor
biology matters. Clin Cancer Res. 7:2155–2158. 2001.
Clin Cancer Res. 7:2228–2236. 2001.
|
|
206
|
Ferrario A, Rucker N, Wong S, Luna M and
Gomer CJ: Survivin, a member of the inhibitor of apoptosis family,
is induced by photodynamic therapy and is a target for improving
treatment response. Cancer Res. 67:4989–4995. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
207
|
Hasenstein JR, Shin HC, Kasmerchak K,
Buehler D, Kwon GS and Kozak KR: Antitumor activity of Triolimus: a
novel multidrug-loaded micelle containing Paclitaxel, Rapamycin,
and 17-AAG. Mol Cancer Ther. 11:2233–2242. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
208
|
Solar P, Ferenc P, Koval J, et al:
Photoactivated hypericin induces downregulation of HER2 gene
expression. Radiat Res. 175:51–56. 2011. View Article : Google Scholar
|
|
209
|
Chen SM, Guo CL, Shi JJ, et al: HSP90
inhibitor AUY922 abrogates up-regulation of RTKs by mTOR inhibitor
AZD8055 and potentiates its antiproliferative activity in human
breast cancer. Int J Cancer. 135:2462–2474. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
210
|
Banerji U, Sain N, Sharp SY, et al: An in
vitro and in vivo study of the combination of the heat shock
protein inhibitor 17-allylamino-17-demethoxygeldanamycin and
carboplatin in human ovarian cancer models. Cancer Chemother
Pharmacol. 62:769–778. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
211
|
Gray PJ Jr, Stevenson MA and Calderwood
SK: Targeting Cdc37 inhibits multiple signaling pathways and
induces growth arrest in prostate cancer cells. Cancer Res.
67:11942–11950. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
212
|
Paduano F, Villa R, Pennati M, et al:
Silencing of survivin gene by small interfering RNAs produces
supra-additive growth suppression in combination with
17-allylamino-17-demethoxygeldanamycin in human prostate cancer
cells. Mol Cancer Ther. 5:179–186. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
213
|
Gandhi N, Wild AT, Chettiar ST, et al:
Novel Hsp90 inhibitor NVP-AUY922 radiosensitizes prostate cancer
cells. Cancer Biol Ther. 14:347–356. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
214
|
Ku S, Lasorsa E, Adelaiye R, Ramakrishnan
S, Ellis L and Pili R: Inhibition of hsp90 augments docetaxel
therapy in castrate resistant prostate cancer. PLoS One.
9:e1036802014. View Article : Google Scholar : PubMed/NCBI
|
|
215
|
Zhao M, Ma J, Zhu HY, et al: Apigenin
inhibits proliferation and induces apoptosis in human multiple
myeloma cells through targeting the trinity of CK2, Cdc37 and
Hsp90. Mol Cancer. 10:1042011. View Article : Google Scholar : PubMed/NCBI
|
|
216
|
Shammas MA, Koley H, Bertheau RC, et al:
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro
and in vivo. Leukemia. 22:1410–1418. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
217
|
Duus J, Bahar HI, Venkataraman G, et al:
Analysis of expression of heat shock protein-90 (HSP90) and the
effects of HSP90 inhibitor (17-AAG) in multiple myeloma. Leuk
Lymphoma. 47:1369–1378. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
218
|
Francis LK, Alsayed Y, Leleu X, et al:
Combination mammalian target of rapamycin inhibitor rapamycin and
HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has
synergistic activity in multiple myeloma. Clin Cancer Res.
12:6826–6835. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
219
|
Cervantes-Gomez F, Nimmanapalli R and
Gandhi V: ATP analog enhances the actions of a heat shock protein
90 inhibitor in multiple myeloma cells. J Pharmacol Exp Ther.
339:545–554. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
220
|
Sydor JR, Normant E, Pien CS, et al:
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone
hydrochloride (IPI-504), an anti-cancer agent directed against
Hsp90. Proc Natl Acad Sci USA. 103:17408–17413. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
221
|
Heimberger T, Andrulis M, Riedel S, et al:
The heat shock transcription factor 1 as a potential new
therapeutic target in multiple myeloma. Br J Haematol. 160:465–476.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
222
|
Sugimoto K, Sasaki M, Isobe Y, et al:
Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative
leukemia cell lines through the depletion of Chk1. Oncogene.
27:3091–3101. 2008. View Article : Google Scholar
|
|
223
|
Haaland I, Opsahl JA, Berven FS, et al:
Molecular mechanisms of nutlin-3 involve acetylation of p53,
histones and heat shock proteins in acute myeloid leukemia. Mol
Cancer. 13:1162014. View Article : Google Scholar : PubMed/NCBI
|
|
224
|
Rahmani M, Yu C, Dai Y, et al:
Coadministration of the heat shock protein 90 antagonist
17-allylamino-17-demethoxygeldanamycin with suberoylanilide
hydroxamic acid or sodium butyrate synergistically induces
apoptosis in human leukemia cells. Cancer Res. 63:8420–8427.
2003.PubMed/NCBI
|
|
225
|
Jia W, Yu C, Rahmani M, et al: Synergistic
antileukemic interactions between 17-AAG and UCN-01 involve
interruption of RAF/MEK- and AKT-related pathways. Blood.
102:1824–1832. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
226
|
Yao Q, Nishiuchi R, Kitamura T and Kersey
JH: Human leukemias with mutated FLT3 kinase are synergistically
sensitive to FLT3 and Hsp90 inhibitors: the key role of the STAT5
signal transduction pathway. Leukemia. 19:1605–1612. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
227
|
Mesa RA, Loegering D, Powell HL, et al:
Heat shock protein 90 inhibition sensitizes acute myelogenous
leukemia cells to cytarabine. Blood. 106:318–327. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
228
|
George P, Bali P, Annavarapu S, et al:
Combination of the histone deacetylase inhibitor LBH589 and the
hsp90 inhibitor 17-AAG is highly active against human CML-BC cells
and AML cells with activating mutation of FLT-3. Blood.
105:1768–1776. 2005. View Article : Google Scholar
|
|
229
|
George P, Bali P, Cohen P, et al:
Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3
kinase inhibitor PKC412 is highly effective against human acute
myelogenous leukemia cells with mutant FLT-3. Cancer Res.
64:3645–3652. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
230
|
Radujkovic A, Schad M, Topaly J, et al:
Synergistic activity of imatinib and 17-AAG in imatinib-resistant
CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein
function by 17-AAG. Leukemia. 19:1198–1206. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
231
|
Rao R, Fiskus W, Yang Y, et al: HDAC6
inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone
function in human leukemia cells. Blood. 112:1886–1893. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
232
|
McCaig AM, Cosimo E, Leach MT and Michie
AM: Dasatinib inhibits B cell receptor signalling in chronic
lymphocytic leukaemia but novel combination approaches are required
to overcome additional pro-survival microenvironmental signals. Br
J Haematol. 153:199–211. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
233
|
Walsby EJ, Lazenby M, Pepper CJ, Knapper S
and Burnett AK: The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K
and IKK signalling pathways and synergizes with cytarabine in acute
myeloid leukaemia cells. Br J Haematol. 161:57–67. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
234
|
Best OG and Mulligan SP: Heat shock
protein-90 inhibitor, NVP-AUY922, is effective in combination with
fludarabine against chronic lymphocytic leukemia cells cultured on
CD40L-stromal layer and inhibits their activated/proliferative
phenotype. Leuk Lymphoma. 53:2314–2320. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
235
|
Robles AI, Wright MH, Gandhi B, et al:
Schedule-dependent synergy between the heat shock protein 90
inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and
doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Clin Cancer Res. 12:6547–6556. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
236
|
Rao R, Lee P, Fiskus W, et al:
Co-treatment with heat shock protein 90 inhibitor
17-dimethylaminoethylamino-17-demethoxygeldanamycin (DMAG) and
vorinostat: a highly active combination against human mantle cell
lymphoma (MCL) cells. Cancer Biol Ther. 8:1273–1280. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
237
|
Abramson JS, Chen W, Juszczynski P, et al:
The heat shock protein 90 inhibitor IPI-504 induces apoptosis of
AKT-dependent diffuse large B-cell lymphomas. Br J Haematol.
144:358–366. 2009. View Article : Google Scholar
|
|
238
|
Premkumar DR, Arnold B, Jane EP and
Pollack IF: Synergistic interaction between 17-AAG and
phosphatidylinositol 3-kinase inhibition in human malignant glioma
cells. Mol Carcinog. 45:47–59. 2006. View Article : Google Scholar
|
|
239
|
Premkumar DR, Arnold B and Pollack IF:
Cooperative inhibitory effect of ZD1839 (Iressa) in combination
with 17-AAG on glioma cell growth. Mol Carcinog. 45:288–301. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
240
|
Jane EP and Pollack IF: The heat shock
protein antagonist 17-AAG potentiates the activity of enzastaurin
against malignant human glioma cells. Cancer Lett. 268:46–55. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
241
|
Choi EJ, Cho BJ, Lee DJ, et al: Enhanced
cytotoxic effect of radiation and temozolomide in malignant glioma
cells: targeting PI3K-AKT-mTOR signaling, HSP90 and histone
deacetylases. BMC Cancer. 14:172014. View Article : Google Scholar : PubMed/NCBI
|
|
242
|
Bull EE, Dote H, Brady KJ, et al: Enhanced
tumor cell radiosensitivity and abrogation of G2 and S phase arrest
by the Hsp90 inhibitor
17-(dimethylaminoethylamino)-17-demethoxygeldanamycin. Clin Cancer
Res. 10:8077–8084. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
243
|
Wachsberger PR, Lawrence YR, Liu Y, et al:
Hsp90 inhibition enhances PI-3 kinase inhibition and
radiosensitivity in glioblastoma. J Cancer Res Clin Oncol.
140:573–582. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
244
|
Gallerne C, Prola A and Lemaire C: Hsp90
inhibition by PU-H71 induces apoptosis through endoplasmic
reticulum stress and mitochondrial pathway in cancer cells and
overcomes the resistance conferred by Bcl-2. Biochim Biophys Acta.
1833:1356–1366. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
245
|
Lin CC, Tu CF, Yen MC, et al: Inhibitor of
heat-shock protein 90 enhances the antitumor effect of DNA vaccine
targeting clients of heat-shock protein. Mol Ther. 15:404–410.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
246
|
Roh JL, Kim EH, Park HB and Park JY: The
Hsp90 inhibitor 17-(allylamino)-17-demethoxygeldanamycin increases
cisplatin antitumor activity by inducing p53-mediated apoptosis in
head and neck cancer. Cell Death Dis. 4:e9562013. View Article : Google Scholar : PubMed/NCBI
|
|
247
|
Bagatell R, Beliakoff J, David CL, Marron
MT and Whitesell L: Hsp90 inhibitors deplete key anti-apoptotic
proteins in pediatric solid tumor cells and demonstrate synergistic
anticancer activity with cisplatin. Int J Cancer. 113:179–188.
2005. View Article : Google Scholar
|
|
248
|
Fu W, Sharma SS, Ma L, et al: Apoptosis of
osteosarcoma cultures by the combination of the cyclin-dependent
kinase inhibitor SCH727965 and a heat shock protein 90 inhibitor.
Cell Death Dis. 4:e5662013. View Article : Google Scholar : PubMed/NCBI
|
|
249
|
Mimnaugh EG, Xu W, Vos M, Yuan X and
Neckers L: Endoplasmic reticulum vacuolization and
valosin-containing protein relocalization result from simultaneous
hsp90 inhibition by geldanamycin and proteasome inhibition by
velcade. Mol Cancer Res. 4:667–681. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
250
|
Martins AS, Ordonez JL, Garcia-Sanchez A,
et al: A pivotal role for heat shock protein 90 in Ewing sarcoma
resistance to anti-insulin-like growth factor 1 receptor treatment:
in vitro and in vivo study. Cancer Res. 68:6260–6270. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
251
|
Neznanov N, Gorbachev AV, Neznanova L, et
al: Anti-malaria drug blocks proteotoxic stress response:
anti-cancer implications. Cell Cycle. 8:3960–3970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
252
|
Enomoto A, Fukasawa T, Takamatsu N, et al:
The HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin
modulates radiosensitivity by downregulating serine/threonine
kinase 38 via Sp1 inhibition. Eur J Cancer. 49:3547–3558. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
253
|
Chinn DC, Holland WS, Yoon JM, Zwerdling T
and Mack PC: Anti-tumor activity of the HSP90 inhibitor SNX-2112 in
pediatric cancer cell lines. Pediatr Blood Cancer. 58:885–890.
2012. View Article : Google Scholar
|
